Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of private equity acquisition of US hospitals on patient outcomes: A systematic review.

Journal of hospital medicine·2026
Same author

Risk Factors for Urinary Tract Infections in Patients with Multiple Sclerosis.

Neurology India·2026
Same author

Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis: It is Safe but Does Not Stop Progression.

The Journal of the Association of Physicians of India·2025
Same author

Trajectory of Hematoma Growth and Functional Recovery after Intracerebral Hemorrhage: A Latent Class Analysis of Blood Pressure in Acute Stroke Collaboration Data.

Cerebrovascular diseases (Basel, Switzerland)·2025
Same author

A rapid onset of Guillain-Barre syndrome following spinal anesthesia for knee arthroscopy: a case report.

Journal of medical case reports·2025
Same author

Unveiling epilepsia partialis continua as an early indicator of HIV encephalitis.

Indian journal of sexually transmitted diseases and AIDS·2025

Related Experiment Video

Updated: Jun 9, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Beta-interferons in multiple sclerosis: a single center experience in India.

Salil Gupta1, R Varadarajulu, R K Ganjoo

  • 1Department of Neurology, Command Hospital Air Force, Bangalore, India. chickusalil@yahoo.com

Annals of Indian Academy of Neurology
|September 4, 2010
PubMed
Summary

Beta-interferon therapy effectively reduced relapses in Indian patients with multiple sclerosis (MS). This study found beta-interferons to be safe and beneficial for managing MS in this population.

Keywords:
Adverse eventsIndian patientsbeta-interferonmultiple sclerosis

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Experiment Videos

Last Updated: Jun 9, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) presentation and progression may differ between Indian-Asian and Western populations.
  • The efficacy of beta-interferon treatment in Indian MS patients remains under investigation.

Purpose of the Study:

  • To evaluate the effectiveness of beta-interferon in reducing relapse rates among Indian patients diagnosed with multiple sclerosis.
  • To assess the safety and tolerability profile of beta-interferon therapy in this demographic.

Main Methods:

  • A cohort of 16 Indian patients with relapsing-remitting or secondary progressive multiple sclerosis (MS) and at least two relapses were initiated on beta-interferon.
  • Patients received either interferon beta-1a (Avonex®) or interferon beta-1b (Betaferon®) and were followed for 1-3 years.
  • Clinical outcomes, including relapse rates and Kurtzke Expanded Disability Status Scale (EDSS) scores, were monitored.

Main Results:

  • The mean annual relapse rate decreased significantly after initiating beta-interferon therapy.
  • Fifteen out of sixteen patients experienced no relapses or disease progression during the follow-up period.
  • The treatment demonstrated a favorable side effect profile, with manageable fever and few psychiatric adverse events requiring discontinuation.

Conclusions:

  • Beta-interferon therapy is a safe and effective treatment option for Indian patients suffering from relapsing-remitting or secondary progressive multiple sclerosis.
  • The findings support the use of beta-interferons to manage MS in the Indian population, mirroring efficacy seen in Western cohorts.